ADCs and Radiopharma Lead the Mid-April Deal Wave; 22,000+ MNC Layoffs Reshape the Industry

• ADCs remain the single most-traded modality: within the window, Lilly (CrossBridge) and the still-active Gilead/Tubulis transaction both center on ADC chemistry.
• Radiopharma becomes a board-level question: the Regeneron × Telix tie-up is notable because a top-5 antibody house is now signaling that radioligand manufacturing is a capability it will partner for rather than build.
• China-to-West licensing continues to set the pace: GSK–Frontier ($40M up / $963M total) and AbbVie–Haisco ($30M up / $745M total) fit the Q1 2026 data showing average deal size up ~76% vs. 2025, led by Chinese-originated assets.
• Upfront compression is structural, not transient: across the four headline licensing deals of the week, upfronts hovered in the $30–40M range against total biobuck packages of $700M–$1B+ — consistent with the ~6% upfront ratio seen industry-wide in Q1 2026.
• What to watch next week: obesity/GLP-1 licensing (still the single highest-value therapeutic category for 2026), further Big Tech / AI-biotech crossovers following Anthropic's ~$400M all-stock acquisition of Coefficient Bio earlier this month, and potential mid-cap consolidation into the back half of the 2025–2030 patent cliff.

Across 2025 and 2026-YTD disclosures (WARN filings, company statements, and tracker data), the cuts clustered in five functional areas, in approximate order of impact:

• Commercial & Sales (primary-care and specialty reps). The single largest functional bucket. Driven by (a) LoE events shrinking detailable promotional inventory, (b) digital/omnichannel replacing in-person reach, and (c) consolidation of therapeutic-area field forces.
• General & Administrative / Corporate Functions. Finance back-office, HR operations, procurement, real-estate, IT service desk. Pfizer, Merck, and Bayer all explicitly named G&A as the first layer to go.
• R&D Support & Early Discovery. Not senior MDs/PhDs, but lab-based early-discovery headcount (medicinal chemistry, in-vitro biology, screening ops) — precisely the functions now being outsourced to CROs or replaced by AI-powered in-silico workflows.
• Manufacturing (site-specific closures). Merck's Pennsylvania site, GSK's Cambridge MA site conversion, Astellas' Universal Cells facility, Gilead's Oceanside wind-down. Site rationalization tied to portfolio concentration, not blanket offshoring.
• Middle Management. Bayer's 'leaner and faster' program and Novartis' restructuring both explicitly de-layered management as a design principle rather than an incidental outcome.

The mirror image of the cuts is a clear, sustained hiring bias toward roles that either (a) enable AI/data-driven productivity, (b) manage externalized/partnered R&D, or (c) sit inside bottleneck regulatory and clinical workflows. Top demand areas in 2025-2026:

• Clinical Data Scientists & Biostatisticians with AI fluency. Hiring managers report 70%+ difficulty filling the 'domain + AI' combined profile.
• AI / ML Engineers embedded in Drug Discovery. Especially generative-chemistry, protein-design, and target-ID specialists.
• Digital Health / Real-World Evidence (RWE) leads. Driven by payer and regulatory demand for outcomes data.
• Regulatory Affairs & Pharmacovigilance specialists. Workload rising as FDA itself lost ~3,859 staff in 2025 and another ~473 in early 2026, shifting review burden onto sponsors.
• Clinical Operations (CRAs, clinical project managers). US clinical trials market ~$43.5B (2025) → ~$46.2B (2026); sustained growth underwrites demand.
• Biomanufacturing engineers (cell/gene, ADC, radioligand). Aligned with the modalities driving the 2026 deal wave.
• Business Development & Licensing professionals. Direct beneficiaries of the 'make-to-buy' shift — in-licensed assets need diligence, structuring, and alliance management.
• Medical Affairs / MSLs in specialty therapeutic areas. Oncology, obesity/cardiometabolic, immunology, rare disease.

AI as a productivity lever, not (yet) a headcount replacer

AI's 2025–2026 impact inside big pharma has been overwhelmingly productivity-driven rather than replacement-driven: admin automation, trial-protocol drafting, medical-writing, literature review, and target triage. Pfizer CEO Albert Bourla's framing — 'We didn't just cut cost, what we did is we improved productivity ... the main lever was the successful deployment of AI' — has become the de facto industry script. Leadership consistently declines to attribute layoffs directly to AI, because many scientific, clinical, and regulatory roles still require judgment and domain context that current AI cannot fully replicate. The functional reality, however, is that AI enables the same R&D and commercial throughput at a lower headcount, which shows up in the P&L as cuts to G&A, commercial, and discovery-support functions first.

The 'make-to-buy' shift in R&D

The structural companion to AI is externalization. Big pharma is now outsourcing close to half of its R&D, and CRO/CDMO spend is compounding at ~12–13% annually against a 7–8% underlying R&D spend growth rate. Executives project another 10–30% uplift in externalized-R&D spend. In parallel, the in-licensing side has exploded: Q1 2026 licensing value of $77.3B and average deal size of $1.3B (up ~76% vs. 2025) confirm that pipeline replenishment is increasingly being bought rather than built. The logical consequence is a steady wind-down of in-house discovery and early-development headcount, offset by ramp-ups in BD&L, alliance management, external innovation, and data/AI functions that make a buy-first model work.

Patent cliff as the background forcing function

Underneath both AI and make-to-buy sits the $300B+ branded-revenue patent cliff running from 2025 through 2030 (Humira follow-ons, Keytruda, Eliquis, Stelara, Xarelto, and others). Cost structures built for peak-revenue years must be re-sized before LoE hits — which is why 2025 layoffs ran ahead of the actual revenue decline. Expect the functional mix of cuts (commercial > G&A > discovery-support > manufacturing site-specific) to continue into 2026 and 2027, with hiring remaining selectively aggressive in AI, data, BD&L, regulatory, and specialty manufacturing.

• Layoff intensity decelerates in 2026 (EY: <5% of headcount) but cuts do not stop; commercial/primary-care field forces and G&A remain the most exposed.
• AI-enabled productivity becomes the default operating model; companies that have not industrialized AI by end-2026 will face a second wave of cost-cutting in 2027.
• Externalization and in-licensing grow faster than in-house R&D; the BD&L function becomes a gating-rate limiter on pipeline growth.
• Talent scarcity in AI + domain, biomanufacturing, and regulatory will continue — compensation pressure in these niches rises even as the overall sector reduces headcount.
• Strategic implication for MNCs: workforce plans, not just pipelines, need to be redesigned around a buy-first, AI-augmented, externalized operating model.

For readers with assets or intros that match the mandates above, the following cross-reference summarizes what Biolink can route directly to the relevant buyer or fund.

A China-based biotech is seeking global partners for a first-in-class (FIC) immunotherapy platform targeting autoimmune diseases. The platform is built on a proprietary antigen-specific tolerance technology designed to modulate immune response without systemic immunosuppression — a mechanism that, if validated, would directly address the central limitation of currently marketed biologics in this space.

Why this asset matches the board

The lead asset is Phase II, and the platform produces multiple FIC programs in autoimmune disease — squarely within the autoimmune mandate from Western buyers. For the geographic-arbitrage fund model the Phase II GD program could also serve as a candidate for a Western Phase II/III re-read with fund capital, particularly given the clean Phase I safety profile. For Newco discussions, the breadth of indications (GD, TED, MS, T1D) plus commercial-stage validation of the parent company make this a platform-level play rather than a single-asset play.

• Featured license-out (autoimmune platform) — BD@biorichinc.com
• Asset submissions for Western buyers or fund mandates — route via Biolink Weekly BD inbox (include modality, stage, last clinical readout, territory availability).
• Role cross-reference — see the Job Board for BD&L talent searches that may pair with these mandates (e.g., Heads of BD&L, VP BD, licensing counsel).

Biolink Weekly — Section 4, BD&L Opportunity Board. Prepared April 20, 2026. Buyer and fund mandates are summarized from direct briefings; details may evolve prior to execution. Biolink does not represent any named party unless explicitly stated.